Colchicine ad CVD risk

Could Old Gout Drug Offer New CV Benefits?

Colchicine use was associated with fewer cardiovascular events and lower all-cause mortality

Nancy Walsh  Senior Staff Writer, MedPage Today

The elevated risk of cardiovascular events among patients with gout declined in those who used colchicine, an observational study found.

The incidence rate ratios among colchicine users compared with non-users were 0.52 (95% CI 0.29-0.92) for myocardial infarction, 0.34 (95% CI 0.14-0.71) for stroke, and 0.79 (95% CI 0.24-2.39) for transient ischemic attack, according to Daniel H. Solomon, MD, and colleagues from Brigham and Women's Hospital in Boston.

After adjustment for all covariates including age, sex, race, history of CV disease, diabetes, and hypertension, and the use of medications such as statins and aspirin, the risk of a composite CV endpoint that included all these events was 49% lower among gout patients who took colchicine (HR 0.51, 95% CI 0.30-0.88, P=0.016), the researchers reported online in Annals of the Rheumatic Diseases./.../